
Opinion|Videos|September 6, 2024
Key Factors to Consider when Switching to Biosimilars
Author(s)Sophia Humphreys, PharmD, MHA
Dr Humphreys discusses key factors to consider when switching to biosimilars.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- To what extent should the pharmacy team prioritize supporting the switch from a reference product to a biosimilar, and what factors should be considered in making this decision?
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5






















